Wei Zhou is founder, president, and CEO of Centrillion Technologies – a company that creates transformative genomic technologies by leveraging engineering and biochemistry breakthroughs to accelerate discovery in human health and the environment.
While a student at Stanford, he joined the pioneering genomic technology start-up Affymetrix (now NASDAQ: AFFX) where a generation of future industry leaders and scientists were inspired to change the world for the better through genomics. He continues to be fascinated by the profound and positive impact of genomic technologies in scientific research, health care, agriculture, and other fields despite the severe limitations of current genomic technologies and is passionate about making genomic technology accurate and accessible.
Prior to founding Centrillion, Zhou was a partner at the technology law firm Wilson Sonsini Goodrich & Rosati where he advised life sciences, clean-tech and digital media companies, and venture capital investors. He also served as a senior advisor to the global law firm Covington and Burling. At Affymetrix, he was a vice president of intellectual property and advanced technology until 2008. He was also credited with building Affymetrix’ rapidly growing China business.
Zhou received his doctorate from Virginia Tech (John Lee Pratt Fellow), his postdoctoral training from Emory University Medical School, and his J.D .from Stanford University Law School (Associate Editor, Stanford Law Review). He is also a graduate of Harvard Business School’s General Management Program.